Direct Effects of Empagliflozin on Extracellular Matrix Remodelling in Human Cardiac Myofibroblasts: Novel Translational Clues to Explain EMPA-REG OUTCOME Results

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis

Ele Ferrannini, Michael Mark, Eric Mayoux · Diabetes Care · 2016 · 969 citations

Medicine, Cardiology, Pharmacology +17

Genetic lineage tracing defines myofibroblast origin and function in the injured heart

Onur Kanisicak, Hadi Khalil, Malina J. Ivey et al. · Nature Communications · 2016 · 907 citations · Full text

Life Sciences, Cell Biology, Genetics +15

Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits

Antonius Baartscheer, Cees A. Schumacher, Rob C. I. Wüst et al. · Diabetologia · 2016 · 652 citations · Full text

Medicine, Cardiology, Pharmacology +16

Specialized fibroblast differentiated states underlie scar formation in the infarcted mouse heart

Xing Fu, Hadi Khalil, Onur Kanisicak et al. · Journal of Clinical Investigation · 2018 · 647 citations · Full text

Life Sciences, Cardiology, Cell Biology +17